Key result
A novel monoclonal antibody, 5B6, enabled the development of a universal ELISA assay to specifically detect the protective intact 146S antigen of all FMDV serotypes in vaccine samples.
A novel monoclonal antibody enables a universal ELISA test to specifically detect protective intact FMDV particles in vaccines, potentially enhancing vaccination program effectiveness.
May facilitate pan-serotype FMDV vaccine antigen detection; leaves open prospective validation before routine adoption.
Foot-and-mouth disease virus (FMDV) causes an economically devastating disease of livestock that is controlled in endemic areas by vaccines containing intact inactivated FMDV particles. In this study, a novel monoclonal antibody named 5B6 has been identified and characterised, that permits the detection of all serotypes of FMDV via a conserved epitope near the N-terminus of the VP4 capsid protein. The antibody recognises intact virus particles known as 146S (the protective antigen) which contain VP4 and not dissociated capsids known as 12S (poorly protective antigen) which lack VP4. This allowed the development of a universal assay to specifically detect the protective antigen in vaccine samples using a simple ELISA. Such a test could be used to assess the quality of formulated vaccine following manufacture or prior to administration, or to assess unformulated vaccine antigen, and would be of great utility to enhance the effectiveness of FMD vaccination programmes.
No takes yet. Share an insight, caveat, or question.
Berryman et al. (2025) studied Foot-and-mouth disease. Monoclonal antibody 5B6-based ELISA was evaluated on Detection of intact virus particles (146S) containing VP4. A novel monoclonal antibody, 5B6, enabled the development of a universal ELISA assay to specifically detect the protective intact 146S antigen of all FMDV serotypes in vaccine samples.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: